RDEA: Summary for Ardea Biosciences, Inc. - Yahoo! Canada Finance

	Sign In [New User? Sign Up]	Finance Home \|Help

Tuesday, November 24, 2009, 5:12am EST - Canadian Markets open in 4 hours and 18 minutes.

To create a watchlist or portfolio of shares, Sign-in or Register

Ardea Biosciences, Inc. (RDEA)

On Nov 23: 14.02 USD 0.00 (0.00%)

MORE ON RDEA

Quotes

Summary

Charts

News & Info

Company

Analyst Coverage

Ownership

Financials

Ardea Biosciences, Inc. (NGM:RDEA) Delayed quote data

Last Trade:	14.02 USD
Trade Time:	Nov 23
Change:	0.00 (0.00%)
Prev Close:	14.02
Open:	N/A
Bid:	N/A
Ask:	N/A
1y Target Est:	25.25

Day's Range:	N/A - N/A
52wk Range:	7.06 - 21.35
Volume:	0
Avg Vol (3m):	87,273.8
Market Cap:	258.18M
P/E (ttm):	N/A
EPS (ttm):	-2.14
Div & Yield:	N/A (N/A%)

1d 5d 3m 6m 1y 2y 5y max

Add RDEA to Portfolio

Download Data

HEADLINES

•	ARDEA BIOSCIENCES, INC./DE Financials
	EDGAR Online Financials (Fri, Nov 13)

•	New Star Analyst Rankings for Ardea Biosciences, Inc.
	StarMine (Tue, Nov 10)

•	ARDEA BIOSCIENCES, INC./DE Files SEC form 8-K, Results of Operations and Financial Condition
	EDGAR Online (Fri, Nov 6)

•	Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results
	PRNewswire (Fri, Nov 6)

•	ARDEA BIOSCIENCES, INC./DE Files SEC form 8-K, Regulation FD Disclosure
	EDGAR Online (Tue, Nov 3)

•	Ardea Biosciences to Present at Three Upcoming Investor Conferences
	Business Wire (Wed, Oct 28)

•	Ardea Presents Gout Data
	Zacks.com (Thu, Oct 22)

•	ARDEA BIOSCIENCES, INC./DE Files SEC form 8-K, Regulation FD Disclosure
	EDGAR Online (Mon, Oct 19)

•	Ardea Biosciences Announces Additional Positive Results from a Phase 2a Study of RDEA594 at the 2009 ACR/ARHP Annual Scientific Meeting
	Business Wire (Mon, Oct 19)

•	Ardea Biosciences to Present Results from a Phase 2a Study of RDEA594 at the 2009 ACR/ARHP Annual Scientific Meeting
	Business Wire (Wed, Sep 30)

•	Ardea Biosciences to Present at Three Upcoming Investor Conferences
	Business Wire (Wed, Sep 16)

More Headlines for RDEA...

ANALYST

EPS Est (next year) (Dec-09) :	-1.59
EPS Est (in 2 years) (Dec-10) :	-2.12
Avg Rec (current)*:	1.4
PEG Ratio:	N/A

* (Strong Buy) 1.0 - 5.0 (Strong Sell)

Analyst Opinion - Estimates

BUSINESS SUMMARY

Ardea Biosciences, Inc., a biotechnology company, focuses on the discovery and development of small-molecule therapeutics for the treatment of gout, human immunodeficiency virus (HIV), cancer, and inflammatory diseases in the United States.

Full Company Profile

Add to Portfolio

Email to a Friend

•